Citadel Advisors
NTLA icon

Citadel Advisors’s Intellia Therapeutics NTLA Stock Holding History

Citadel Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.87M Sell
458,241
-492,009
-52% -$6.27M ﹤0.01% 4079
2025
Q4 		$8.54M Buy
950,250
+939,895
+9,077% +$12.9M ﹤0.01% 3461
2025
Q3 		$179K Sell
10,355
-699,626
-99% -$8.62M ﹤0.01% 11378
2025
Q2 		$6.66M Sell
709,981
-2,047,587
-74% -$16.8M ﹤0.01% 3634
2025
Q1 		$19.6M Buy
2,757,568
+263,498
+11% +$2.66M ﹤0.01% 2057
2024
Q4 		$29.1M Buy
2,494,070
+1,504,631
+152% +$23.5M 0.01% 1775
2024
Q3 		$20.3M Buy
989,439
+226,759
+30% +$5.23M ﹤0.01% 2032
2024
Q2 		$17.1M Sell
762,680
-128,104
-14% -$3.05M ﹤0.01% 2159
2024
Q1 		$24.5M Sell
890,784
-368,508
-29% -$10.2M ﹤0.01% 1864
2023
Q4 		$38.4M Sell
1,259,292
-710,891
-36% -$20.4M 0.01% 1395
2023
Q3 		$62.3M Buy
1,970,183
+365,555
+23% +$14.2M 0.01% 912
2023
Q2 		$65.4M Buy
1,604,628
+436,114
+37% +$17.7M 0.01% 846
2023
Q1 		$43.6M Sell
1,168,514
-30,171
-3% -$1.18M 0.01% 1196
2022
Q4 		$41.8M Buy
1,198,685
+641,551
+115% +$30.5M 0.01% 1265
2022
Q3 		$31.2M Buy
557,134
+163,196
+41% +$10.1M 0.01% 1440
2022
Q2 		$20.4M Sell
393,938
-92,495
-19% -$4.7M 0.01% 1836
2022
Q1 		$35.3M Buy
486,433
+279,591
+135% +$23.7M 0.01% 1399
2021
Q4 		$24.5M Buy
206,842
+67,336
+48% +$8.44M 0.01% 1805
2021
Q3 		$18.7M Sell
139,506
-172,591
-55% -$26.1M ﹤0.01% 2101
2021
Q2 		$50.5M Sell
312,097
-395,906
-56% -$30.8M 0.01% 1115
2021
Q1 		$56.8M Sell
708,003
-421,396
-37% -$28.3M 0.01% 951
2020
Q4 		$61.4M Buy
1,129,399
+293,613
+35% +$10.7M 0.02% 811
2020
Q3 		$16.6M Buy
835,786
+91,359
+12% +$1.9M ﹤0.01% 1737
2020
Q2 		$15.6M Sell
744,427
-152,610
-17% -$2.59M 0.01% 1728
2020
Q1 		$11M Buy
897,037
+253,661
+39% +$3.42M ﹤0.01% 1754
2019
Q4 		$9.44M Buy
643,376
+536,787
+504% +$7.47M ﹤0.01% 2270
2019
Q3 		$1.42M Sell
106,589
-52,254
-33% -$833K ﹤0.01% 5021
2019
Q2 		$2.6M Buy
158,843
+70,739
+80% +$1.11M ﹤0.01% 4085
2019
Q1 		$1.5M Buy
88,104
+62,159
+240% +$927K ﹤0.01% 4914
2018
Q4 		$354K Buy
25,945
+793
+3% +$14.7K ﹤0.01% 6975
2018
Q3 		$720K Buy
+25,152
New +$732K ﹤0.01% 6112
2018
Q2 		– Sell
-65,416
Closed -$1.58M – 9132
2018
Q1 		$1.38M Buy
65,416
+44,876
+218% +$1.1M ﹤0.01% 4311
2017
Q4 		$395K Buy
20,540
+6,530
+47% +$151K ﹤0.01% 6027
2017
Q3 		$348K Buy
+14,010
New +$264K ﹤0.01% 5843

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NTLA Position: Q1 2026 in Review

Citadel Advisors reduced its Intellia Therapeutics (NTLA) stake by 52% in Q1 2026, selling an estimated $6.27M and leaving 458,241 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

Citadel Advisors first reported a position in NTLA in Q3 2017 and has held it in 34 quarters since. The position peaked at $65.4M in Q2 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Citadel Advisors held 458,241 shares of Intellia Therapeutics worth $5.87M as of Q1 2026.
  • Citadel Advisors sold 492,009 Intellia Therapeutics shares in Q1 2026, an estimated $6.27M.
  • Intellia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4079 holding.
  • Citadel Advisors first reported a position in Intellia Therapeutics in Q3 2017 and has held it in 34 quarters since.
  • Citadel Advisors's Intellia Therapeutics position peaked at $65.4M in Q2 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.